GNSZ news just out!
GenSpera Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202
G-202 Data in HCC Patients (Phase I and Phase II) Highly Suggestive of Positive Clinical Activity
http://finance.yahoo.com/news/genspera-releas...00183.html
SAN ANTONIO, June 24, 2014 /PRNewswire/ --
GenSpera, Inc. (GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at 11:15 PDT, in San Diego, CA.
Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study in hepatocellular (HCC) patients who had previously progressed on, or who were intolerant of, sorafenib. Historically, this patient population has a median time to progression of only two months when they enter subsequent clinical trials. Impressively, 80% of patients treated with G-202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study.
Commenting on the Phase I and II data of G-202 in HCC Patients, Dr. Dionne stated, "Our lead candidate, G-202, is demonstrating better than expected clinical results and safety profile. These data are strongly encouraging and highly suggestive of clinical activity in this very challenging patient population. Relative to other drugs currently in advanced trials in HCC patients, G-202 appears to exhibit a better tolerated side effect profile and a larger subset of patients who experience disease stabilization of at least six months. Remarkably, one patient remains on treatment 22 months after initiation of treatment and another patient experienced complete remission of bone pain due to a metastatic lesion to the spinal column. As a result of these data, we are designing a randomized study as the next step toward United States Food and Drug Administration approval of G-202."
Investors can view the company presentation at the Company website: http://www.genspera.com/
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company's website: http://www.genspera.com or follow us on Twitter @GenSperaNews.
About BIO
The 2014 BIO International Convention is June 23-26 at the San Diego Convention Center in San Diego, California.
The BIO International Convention is hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. http://convention.bio.org/2014/
GenSpera Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202
G-202 Data in HCC Patients (Phase I and Phase II) Highly Suggestive of Positive Clinical Activity
http://finance.yahoo.com/news/genspera-releas...00183.html
SAN ANTONIO, June 24, 2014 /PRNewswire/ --
GenSpera, Inc. (GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at 11:15 PDT, in San Diego, CA.
Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study in hepatocellular (HCC) patients who had previously progressed on, or who were intolerant of, sorafenib. Historically, this patient population has a median time to progression of only two months when they enter subsequent clinical trials. Impressively, 80% of patients treated with G-202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study.
Commenting on the Phase I and II data of G-202 in HCC Patients, Dr. Dionne stated, "Our lead candidate, G-202, is demonstrating better than expected clinical results and safety profile. These data are strongly encouraging and highly suggestive of clinical activity in this very challenging patient population. Relative to other drugs currently in advanced trials in HCC patients, G-202 appears to exhibit a better tolerated side effect profile and a larger subset of patients who experience disease stabilization of at least six months. Remarkably, one patient remains on treatment 22 months after initiation of treatment and another patient experienced complete remission of bone pain due to a metastatic lesion to the spinal column. As a result of these data, we are designing a randomized study as the next step toward United States Food and Drug Administration approval of G-202."
Investors can view the company presentation at the Company website: http://www.genspera.com/
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company's website: http://www.genspera.com or follow us on Twitter @GenSperaNews.
About BIO
The 2014 BIO International Convention is June 23-26 at the San Diego Convention Center in San Diego, California.
The BIO International Convention is hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. http://convention.bio.org/2014/
